Skip to content Skip to footer
Subscribe Now
Sandoz
NEWS

Sandoz Launches Tyruko (Biosimilar, Tysabri) in the US

Shots: Sandoz has launched Tyruko, a biosimilar version of Biogen’s Tysabri (natalizumab), for all indications of the reference product, incl. relapsing forms of multiple sclerosis (MS) & mod. to sev. active Crohn’s disease in adults In 2019, Sandoz signed a global commercialization deal with Polpharma for Tyruko, with Polpharma responsible for development & manufacturing of…
November 17, 2025

Read more

Sandoz
NEWS

Sandoz Introduces Tyruko (Biosimilar, Tysabri) for Multiple Sclerosis in Germany 

Shots :  Sandoz has introduced Tyruko (natalizumab), biosimilar of Tysabri for the treatment of r/r multiple sclerosis (RRMS), in Germany which will be available from Feb 1   Polpharma Biologics is responsible for the development, manufacturing and supply of Tyruko while Sandoz holds its commercialization rights in all markets as per a global commercialization agreement signed…
January 31, 2024

Read more